Evogliptin tartrate

• CAT Number: I017429
• CAS Number: 1222102-51-3
• Molecular Formula: C₂₃H₃₂F₃N₃O₉
• Molecular Weight: 551.51
• Purity: ≥95%
• Target: Autophagy
• IUPAC Name: (3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-[(2-methylpropan-2-yl)oxymethyl]piperazin-2-one;(2R,3R)-2,3-dihydroxybutanedioic acid
• InChI: InChI=1S/C19H26F3N3O3.C4H6O6/c1-19(2,3)28-10-16-18(27)24-4-5-25(16)17(26)8-12(23)6-11-7-14(21)15(22)9-13(11)20;5-1(3(7)8)2(6)4(9)10/h7,9,12,16H,4-6,8,10,23H2,1-3H3,(H,24,27);1-2,5-6H,(H,7,8)(H,9,10)/t12-,16-;1-,2-/m11/s1
• InChIKey: RBBXDAJRSNHIJZ-DLDKMZOSSA-N
• SMILES: CC(C)(C)OC[C@@H]1C(=O)NCCN1C(=O)C[C@@H](CC2=CC(=C(C=C2F)F)F)N.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O

Evogliptin tartrate（Cat No.:I017429）is a selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4), which plays a key role in regulating blood sugar levels by breaking down incretin hormones. By inhibiting DPP-4, evogliptin helps increase the levels of active incretin hormones, promoting insulin secretion and reducing glucagon release, both of which help control blood sugar levels in individuals with type 2 diabetes. Evogliptin is often used as an adjunct to diet and exercise to improve glycemic control. It is well-tolerated with a low risk of hypoglycemia and is a valuable treatment option for diabetes management.